Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 9181698, 3 pages
http://dx.doi.org/10.1155/2016/9181698
Case Report

Refractory IgG Warm Autoimmune Hemolytic Anemia Treated with Eculizumab: A Novel Application of Anticomplement Therapy

Department of Medicine, Division of Hematology, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, Room E-725, Montreal, QC, Canada H3T 1E2

Received 30 September 2015; Accepted 9 March 2016

Academic Editor: Akimichi Ohsaka

Copyright © 2016 Kim Ma and Stephen Caplan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. F. Bass, E. T. Tuscano, and J. M. Tuscano, “Diagnosis and classification of autoimmune hemolytic anemia,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 560–564, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Lechner and U. Jäger, “How I treat autoimmune hemolytic anemias in adults,” Blood, vol. 116, no. 11, pp. 1831–1838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Bockorny, J. A. Atienza, and C. A. Dasanu, “Autoimmune manifestations in patients with Waldenström macroglobulinemia,” Clinical Lymphoma, Myeloma and Leukemia, vol. 14, no. 6, pp. 456–459, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Hill, R. P. Rother, X. Wang et al., “Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria,” British Journal of Haematology, vol. 149, no. 3, pp. 414–425, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Varela and R. A. Brodsky, “Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition,” Expert Review of Clinical Immunology, vol. 9, no. 11, pp. 1113–1124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Legendre, C. Licht, P. Muus et al., “Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome,” New England Journal of Medicine, vol. 368, no. 23, pp. 2169–2181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Röth, A. Hüttmann, R. P. Rother, U. Dührsen, and T. Philipp, “Longterm efficacy of the complement inhibitor eculizumab in cold agglutinin disease,” Blood, vol. 113, no. 16, pp. 3885–3886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Gupta and E. S. Wang, “Long-term response of refractory primary cold agglutinin disease to eculizumab therapy,” Annals of Hematology, vol. 93, no. 2, pp. 343–344, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. P. Chao, J. Hong, C. Kunder, L. Lester, S. L. Schrier, and R. Majeti, “Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab,” American Journal of Hematology, vol. 90, no. 1, pp. 78–81, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Barcellini, B. Fattizzo, A. Zaninoni et al., “Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients,” Blood, vol. 124, no. 19, pp. 2930–2936, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Roth, U. Duhrsen, M. Bommer et al., “Complement inhibtion with eculizumab in patients with cold agglutinin disease (CAD): results from a prospective phase II trial (DECADE trial),” in Proceedings of the 57th ASH Annual Meeting and Exposition (ASH '15), Orlando, Fla, USA, December 2015.